AIM ImmunoTech
Ocala, Florida, United States · Biotechnology, Healthcare, Health Care
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical tr
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Ocala, Florida, United States
- Employees
- 32
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (AIM)
- Website
- aimimmuno.com
- Company page
Recent activity at AIM ImmunoTech
- : SEC 8-K (7.01): The Company, AIM ImmunoTech Inc., issued a press release on November 5, 2026, along with a corporate presentation titled 'The Ampligen Opportunity.' This announcement covers forward-looking statements regarding Ampligen's potential to enhance clinical benefits, particularly in the treatment of pancreatic cancer. The Company discusses its business strategy and objectives, regulatory expectations, and the risks involved in pharmaceutical development. This filing serves to inform stakeholders about the Company’s recent developments and strategic direction.
- : SEC 8-K (1.01): On September 8-9, 2026, AIM ImmunoTech Inc. entered into two exchange agreements with Streeterville Capital, LLC. These agreements enabled the conversion of approximately $400,000 of a previously issued promissory note into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. This transaction was previously approved by the Company’s stockholders, aligning with compliance procedures under NYSE American regulations. The strategic implication of this conversion is expected to enhance liquidity and balance the Company’s capital structure effectively.
- : SEC 8-K (1.01): On September 3, 2026, AIM ImmunoTech Inc. entered into two exchange agreements with Streeterville Capital, LLC. These agreements involved the conversion of approximately $450,000 of a previously issued Promissory Note into 1,921,441 shares of the company's common stock at an average conversion price of $0.234 per share. Shareholder approval for this conversion was obtained prior, ensuring compliance with NYSE American requirements. The transaction will potentially enhance the company’s equity base and strengthen its financial position in light of future operational needs.
Employee benefit plans
AIM ImmunoTech files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About AIM ImmunoTech: questions and answers
What does AIM ImmunoTech do?
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical tr
Where is AIM ImmunoTech headquartered?
AIM ImmunoTech is headquartered in Ocala, Florida, United States.
How many employees does AIM ImmunoTech have?
AIM ImmunoTech has about 32 employees.
What is the latest news on AIM ImmunoTech?
On Nov 05, 2026, SEC 8-K (7.01): The Company, AIM ImmunoTech Inc., issued a press release on November 5, 2026, along with a corporate presentation titled 'The Ampligen Opportunity.' This announcement covers forward-looking statements regarding Ampligen's potential to enhance clinical benefits, particularly in the tr
Is AIM ImmunoTech a public company?
Yes. AIM ImmunoTech is publicly traded under the ticker AIM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy